Literature DB >> 16132374

Changes in indication and results after resection of hepatic metastases from noncolorectal primary tumors: a single-institutional review.

Süleyman Yedibela1, Jonas Gohl, Valentina Graz, Mona Kathrin Pfaffenberger, Susanne Merkel, Werner Hohenberger, Thomas Meyer.   

Abstract

BACKGROUND: The isolated occurrence of noncolorectal liver metastases is rare. The available data are inconsistent in terms of indication for surgery, treatment, and outcome, so a generally applicable therapeutic algorithm is currently lacking.
METHODS: A total of 162 patients underwent resection for noncolorectal liver metastases between 1978 and 2001. The patients were divided into two groups from different time periods (group 1, 1978-1989; group 2, 1990-2001) that were similar in terms of number of patients, operating surgeons, and surgical techniques used. The groups were compared, and the data were retrospectively analyzed with regard to indication, survival, and factors predictive for survival.
RESULTS: Resection was performed to remove liver metastases from noncolorectal gastrointestinal carcinoma (n = 50), neuroendocrine tumors (n = 12), genitourinary primary tumors (n = 11), breast carcinoma (n = 24), leiomyosarcoma (n = 15), and metastases from other primary cancers (n = 50). Extrahepatic tumor involvement was seen in 38 (23%) of the 162 cases. Sixty-two (38%) major hepatectomies and 100 (62%) minor resections were performed. In 100 (62%) of 162 patients, a curative resection (R0) could be achieved. Overall 2- and 5-year survival rates of 49% and 26%, respectively, were observed, and the median survival was 23 months. Survival was significantly longer in patients who underwent an R0 resection.
CONCLUSIONS: In selected patients, resection of noncolorectal liver metastases is associated with a 5-year survival rate of up to 50%. Resection of liver metastases from gastrointestinal adenocarcinomas correlates with a poor prognosis. Extrahepatic metastases may be considered a relative contraindication for liver resection.

Entities:  

Mesh:

Year:  2005        PMID: 16132374     DOI: 10.1245/ASO.2005.11.018

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  24 in total

1.  Liver resection for liver metastases from nondigestive endocrine cancer: extrahepatic disease burden defines outcome.

Authors:  Andreas Andreou; Antoine Brouquet; Kishore G S Bharathy; Nancy D Perrier; Eddie K Abdalla; Steven A Curley; Matthias Glanemann; Daniel Seehofer; Peter Neuhaus; Jean-Nicolas Vauthey; Thomas A Aloia
Journal:  Surgery       Date:  2012-02-04       Impact factor: 3.982

2.  Survival Benefits of Surgical Resection in Patients with Recurrent Biliary Tract Carcinoma.

Authors:  Hiroaki Motoyama; Akira Kobayashi; Takahide Yokoyama; Akira Shimizu; Noriyuki Kitagawa; Tsuyoshi Notake; Kentaro Fukushima; Hitoshi Masuo; Takahiro Yoshizawa; Shin-Ichi Miyagawa
Journal:  World J Surg       Date:  2017-11       Impact factor: 3.352

3.  Surgery for liver metastases originating from sarcoma-case series.

Authors:  Maximilian Zacherl; Gerwin A Bernhardt; Johannes Zacherl; Gerald Gruber; Peter Kornprat; Heinz Bacher; Hans-Jörg Mischinger; Reinhard Windhager; Raimund Jakesz; Thomas Grünberger
Journal:  Langenbecks Arch Surg       Date:  2011-07-08       Impact factor: 3.445

4.  Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis.

Authors:  Michael D Staehler; Jessica Kruse; Nicolas Haseke; Thomas Stadler; Alexander Roosen; Alexander Karl; Christian G Stief; Karl W Jauch; Christiane J Bruns
Journal:  World J Urol       Date:  2010-05-04       Impact factor: 4.226

5.  Liver Resection for Non-colorectal Non-neuroendocrine Metastases: Where Do We Stand Today Compared to Colorectal Cancer?

Authors:  Tobias S Schiergens; Juliane Lüning; Bernhard W Renz; Michael Thomas; Sebastian Pratschke; Hao Feng; Serene M L Lee; Jutta Engel; Markus Rentsch; Markus Guba; Jens Werner; Wolfgang E Thasler
Journal:  J Gastrointest Surg       Date:  2016-02-26       Impact factor: 3.452

Review 6.  The benefits of liver resection for non-colorectal, non-neuroendocrine liver metastases: a systematic review.

Authors:  Timothy L Fitzgerald; Jason Brinkley; Shannon Banks; Nasreen Vohra; Zachary P Englert; Emmanuel E Zervos
Journal:  Langenbecks Arch Surg       Date:  2014-08-23       Impact factor: 3.445

Review 7.  Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG).

Authors: 
Journal:  Ann Oncol       Date:  2018-04-01       Impact factor: 32.976

8.  Non-colorectal, non-neuroendocrine, and non-sarcoma metastases of the liver: resection as a promising tool in the palliative management.

Authors:  Moritz Schmelzle; Claus F Eisenberger; Jan Schulte am Esch; Hanno Matthaei; Markus Krausch; Wolfram T Knoefel
Journal:  Langenbecks Arch Surg       Date:  2009-12-09       Impact factor: 3.445

9.  Preoperative Prognostic Factors After Liver Resection for Non-Colorectal, Non-Neuroendocrine Liver Metastases and Validation of the Adam Score in an Asian Population.

Authors:  Dayna P Y Sim; Brian K P Goh; Ser-Yee Lee; Chung-Yip Chan; Iain B H Tan; Peng-Chung Cheow; Premaraj Jeyaraj; Pierce K H Chow; London L P J Ooi; Alexander Y F Chung
Journal:  World J Surg       Date:  2018-04       Impact factor: 3.352

10.  Liver resection for non-colorectal, non-neuroendocrine metastases: analysis of a multicenter study from Argentina.

Authors:  J Lendoire; M Moro; O Andriani; J Grondona; O Gil; G Raffin; J Silva; R Bracco; G Podestá; C Valenzuela; O Imventarza; J Pekolj; E De Santibañes
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.